Sourcing & Product Review
Donor-Derived Material
The preparations described in our protocols are sourced from placental tissue or fluid donated following full-term births from screened mothers. Product review considers donor eligibility, processing methods, sterility testing, and documentation from the supplying laboratory.
A laboratory’s research funding or association with FDA research does not establish FDA approval of a product or its use for a particular condition.
Understanding Safety
Donor screening and controlled processing are important safeguards, but they do not eliminate infection, inflammatory reactions, or other complications. Placental preparations should not be described as carrying zero risk of rejection or autoimmune response.
The exact composition matters: a tissue matrix is not necessarily a living stem cell preparation, and exosomes are cell-derived vesicles rather than self-renewing cells.
Clinical Assessment
Chronic Illness & Systemic Inflammation
When considering patient-derived and donor-derived approaches, we review your overall health, medications, immune status, and procedural risks. Chronic illness or a weakened immune system does not, by itself, establish that your own cells lack vitality or that a donor-derived preparation will provide better outcomes.
Joint & Spine Concerns
Conditions discussed during consultation may include osteoarthritis of the knees, hips, shoulders, and ankles, temporomandibular joint concerns, and degenerative spine symptoms.
These diagnoses require individual evaluation. The proposed use of a placental preparation does not establish that it regenerates cartilage, repairs spinal discs, or restores joint stability.
Peripheral Nerve Hydrodissection
Selected protocols may include discussion of a placental preparation during ultrasound-guided hydrodissection for nerve entrapment. Hydrodissection uses injected fluid to separate a nerve from surrounding tissue restrictions.
The mechanical separation and the additional preparation have distinct roles and risks. Evidence supporting hydrodissection does not automatically establish a benefit from adding placental material.
Supporting Protocols
Three-Day Preconditioning IV Package
Selected plans may include a three-day series of nutrient and oxygen-based infusions before the proposed procedure. We explain each component separately, including its intended purpose and potential risks.
Improved tissue responsiveness or regenerative outcomes from this preconditioning approach have not been established.
Peptide Preparations
Our protocols may also include discussion of BPC-157 and thymosin beta-4 within proposed injection solutions, or CJC-1295 and ipamorelin before treatment.
These preparations require separate consideration of evidence, product quality, regulatory status, and safety. They should not be presented as established methods of activating placental products or enhancing tissue regeneration.
Placement & Follow-Up
When an injection is appropriate, we use real-time ultrasound to visualize relevant anatomy and guide placement. Imaging supports procedural precision while potential risks—including bleeding, infection, pain, and injury to nearby structures—remain.
Before proceeding, we explain the specific product, proposed indication, available evidence, alternatives, and recovery requirements. Follow-up focuses on symptoms, movement, and daily function, with rehabilitation or further evaluation incorporated when needed.
Placental and exosome products are not FDA-approved treatments for the orthopedic and nerve conditions described here. Any proposed use requires review of the applicable regulatory pathway.
